Supplementary Table 1. Baseline Demographic and Clinical Characteristics of Study Sample by Baseline Stage of Diabetic Nephropathy and Progression Status

|                      | Normal Albuminuria | Microalbuminuria | Macroalbuminuria |
|----------------------|--------------------|------------------|------------------|
|                      | Progressed (n) (%) | No Progression (n) (%) | Progressed (n) (%) | No Progression (n) (%) | Progressed (n) (%) | No Progression (n) (%) |
| n (%)                | 2,676 (51.2%)      | 2,547 (48.8%)    | 659 (30.9%)      | 1,477 (69.1%)         | 20 (5.0%)         | 379 (95.0%)          |
| Age*                 | 61.4 (11.4)        | 59.8 (10.6)      | 60.2 (12.1)      | 60.9 (11.9)           | 60.4 (13.0)       | 61.8 (11.7)          |
| % Men†               | 49.0%              | 49.3%            | 61.0%            | 50.9%                 | 70.0%             | 48.8%               |
| Current Smoker*†     | 10.8%              | 8.1%             | 17.9%            | 11.5%                 | 15.0%             | 13.7%               |
| African-American     | 3.0%               | 3.0%             | 2.0%             | 3.0%                  | 5.0%              | 3.4%                |
| Diabetes Duration*†  | 4.7 (4.2)          | 3.8 (3.7)        | 5.8 (4.5)        | 4.8 (4.2)             | 7.4 (5.2)         | 6.0 (4.9)           |
| BMI                  | 34.6 (7.4)         | 34.3 (7.0)       | 34.5 (7.4)       | 34.5 (7.2)            | 33.4 (8.4)        | 34.6 (7.5)          |
| Systolic BP*†        | 137 (14)           | 136 (13)         | 142 (15)         | 139 (14)              | 148 (15)          | 145 (17)            |
| Diastolic BP         | 79 (8)             | 79 (8)           | 80 (9)           | 80 (9)                | 82 (7)            | 81 (9)              |
| A1C*                 | 7.7% (1.7)         | 7.5% (1.6)       | 8.3% (1.9)       | 8.1% (1.8)            | 9.4% (2.4)        | 8.3% (1.9)          |
| LDL-C                | 110 (31)           | 112 (31)         | 109 (35)         | 110 (35)              | 123 (51)          | 109 (40)            |
| eGFR*†               | 88 (27)            | 90 (24)          | 85 (32)          | 91 (35)               | 60 (25)           | 87 (48)             |
| Cardiovascular Disease* | 22.9%           | 15.7%            | 24.1%            | 22.4%                 | 35.0%             | 26.9%               |
| Stroke*              | 7.3%               | 5.0%             | 11.2%            | 8.9%                  | 5.0%              | 13.5%               |
| Heart Failure*       | 7.3%               | 4.7%             | 10.9%            | 10.0%                 | 10.0%             | 15.8%               |

©2011 American Diabetes Association. Published online at http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc11-0475/-/DC1
### Neuropathy*

|       | 19.0% | 15.6% | 23.8% | 20.0% | 20.0% | 25.3% |
|-------|-------|-------|-------|-------|-------|-------|

### Retinopathy*†

|       | 7.0%  | 4.6%  | 14.4% | 9.0%  | 45.0% | 21.9% |
|-------|-------|-------|-------|-------|-------|-------|

### Depression

|       | 22.7% | 23.6% | 21.6% | 20.7% | 25.0% | 24.0% |
|-------|-------|-------|-------|-------|-------|-------|

### ACEi or ARB*

|       | 54.1% | 46.7% | 68.1% | 64.6% | 70.0% | 75.7% |
|-------|-------|-------|-------|-------|-------|-------|

### Other anti-htn Rx*

|       | 54.0% | 44.9% | 55.7% | 51.7% | 70.0% | 63.6% |
|-------|-------|-------|-------|-------|-------|-------|

### Metformin*

|       | 38.1% | 33.1% | 41.7% | 42.1% | 45.0% | 40.4% |
|-------|-------|-------|-------|-------|-------|-------|

### Sulfonylurea*

|       | 47.7% | 40.6% | 54.2% | 50.2% | 75.0% | 51.7% |
|-------|-------|-------|-------|-------|-------|-------|

### Insulin*†

|       | 12.6% | 9.2%  | 22.3% | 15.2% | 35.0% | 21.4% |
|-------|-------|-------|-------|-------|-------|-------|

### Statin

|       | 33.3% | 30.7% | 35.1% | 32.1% | 35.0% | 31.4% |
|-------|-------|-------|-------|-------|-------|-------|

*Normal Albuminuria: Progressed Differs from No Progression, p<0.001
†Microalbuminuria: Progressed Differs from No Progression, p<0.001
‡Macroalbuminuria: Progressed Differs from No Progression, p<0.001
Supplementary Table 2. Clinical Characteristics at Follow-Up of Study Sample by Baseline Stage of Diabetic Nephropathy and Progression Status

|                  | Normal Albuminuria | Microalbuminuria | Macroalbuminuria |
|------------------|--------------------|------------------|------------------|
|                  | Progressed         | No Progression   | Progressed       | No Progression   | Progressed         | No Progression   |
| n (%)            | 2,676 (51.2%)      | 2,547 (48.8%)    | 659 (30.9%)      | 1,477 (69.1%)    | 20 (5.0%)          | 379 (95.0%)      |
| BMI              | 34.2 (7.6)         | 34.0 (7.1)       | 34.2 (7.8)       | 34.1 (7.3)       | 33.0 (7.9)         | 34.1 (7.3)       |
| Systolic BP*†    | 136 (12)           | 133 (10)         | 141 (13)         | 135 (11)         | 144 (9)            | 140 (12)         |
| Diastolic BP*†   | 77 (8)             | 75 (6)           | 78 (9)           | 75 (7)           | 75 (6)             | 75 (7)           |
| A1C*†            | 7.5% (1.3)         | 7.2% (1.0)       | 7.8% (1.5)       | 7.5% (1.1)       | 7.9% (1.2)         | 7.4% (1.2)       |
| LDL-C*†          | 102 (26)           | 99 (23)          | 103 (29)         | 97 (24)          | 103 (29)           | 97 (23)          |
| eGFR‡            | 86 (27)            | 86 (23)          | 80 (29)          | 83 (28)          | 30 (8)             | 70 (47)          |
| Cardiovascular Disease | 0.278              | 0.249            | 0.301            | 0.349            | 0.65               | 0.441            |
| Stroke           | 0.108              | 0.114            | 0.155            | 0.173            | 0.15               | 0.296            |
| Heart Failure    | 0.122              | 0.112            | 0.184            | 0.221            | 0.7                | 0.388            |
| Neuropathy       | 28.9%              | 28.7%            | 34.9%            | 39.9%            | 65.0%              | 52.8%            |
| Retinopathy      | 10.4%              | 8.1%             | 18.7%            | 16.8%            | 55.0%              | 35.4%            |
| Depression*      | 29.0%              | 34.0%            | 27.3%            | 34.1%            | 35.0%              | 39.8%            |
| ACEi or ARB*‡    | 59.9%              | 64.7%            | 63.1%            | 67.2%            | 25.0%              | 67.0%            |
| Other anti-htn Rx* | 59.7%              | 54.7%            | 62.1%            | 62.0%            | 85.0%              | 74.1%            |
**SUPPLEMENTARY DATA**

|                  | 44.4% | 49.5% | 38.1% | 47.1% | 0.0% | 30.9% |
|------------------|-------|-------|-------|-------|------|-------|
| Metformin*†‡     |       |       |       |       |      |       |
| Sulfonylurea*†   | 45.4% | 37.0% | 48.0% | 37.0% | 35.0%| 31.1% |
| Insulin*         | 19.8% | 24.7% | 30.7% | 34.9% | 60.0%| 43.5% |
| Statin*†         | 50.0% | 62.1% | 47.2% | 62.2% | 65.0%| 57.3% |

*Normal Albuminuria: Progressed Differs from No Progression, p<0.001
†Microalbuminuria: Progressed Differs from No Progression, p<0.001
‡Macroalbuminuria: Progressed Differs from No Progression, p<0.001